HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

Autor: Estelle Bourbon, Pierre Sesques, Morgane Gossez, Jérémie Tordo, Emmanuelle Ferrant, Violaine Safar, Florent Wallet, Guillaume Aussedat, Alizée Maarek, Fadhela Bouafia, Lionel Karlin, Dana Ghergus, Camille Golfier, Hélène Lequeu, Anne Lazareth, Vérane Schwiertz, Sébastien Viel, Maryam Idlhaj, Hervé Ghesquières, Guillaume Monneret, Emmanuel Bachy, Fabienne Venet
Přispěvatelé: Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])
Rok vydání: 2023
Předmět:
Zdroj: Blood Advances
Blood Advances, 2023, 7 (5), pp.744-755. ⟨10.1182/bloodadvances.2021006563⟩
ISSN: 2473-9537
2473-9529
DOI: 10.1182/bloodadvances.2021006563
Popis: Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in CAR therapy, we sought to evaluate the evolution of HLA-DR expression on monocytes (mHLA-DR) before and after commercial anti-CD19 CAR T-cell infusion in a large cohort (n = 103) of patients with R/R LBCL and its association with adverse events and treatment response. Cy-Flu-based lymphodepletion (LD) upregulated mHLA-DR in 79% of the cases, whereas in 2l% of cases (15 patients), the mHLA-DR level decreased after LD, and this decrease was associated with poorer outcome. Low mHLA-DR at day minus 7 (D−7) (
Databáze: OpenAIRE
Externí odkaz: